Get access
Clinical & Experimental Allergy

CCL17 and CCL22 attenuate CCL5-induced mast cell migration

Authors


Dr Gunnar Nilsson, Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden. E-mail: Gunnar.Nilsson@genpat.uu.se

Summary

Background Mast cells (MCs) accumulate at sites of allergic mucosal inflammation where they act as central effectors and regulatory cells. Chemokines are believed to be crucial for the recruitment of MCs to sites of inflammation. We recently reported that human umbilical cord blood MCs (CBMCs) expresses the CC chemokine receptors, CCR1 and CCR4. We found a unique response profile to ligands of the respective receptors in which, of all tested ligands, only CCL5/RANTES-induced migration.

Objective To further investigate the function of CCR4 in MCs.

Methods CBMCs were used for competition binding experiments, migration, and intracellular calcium mobilization and release response studies.

Results The natural ligands for CCR4, CCL17/TARC and CCL22/MDC could both compete for binding with radiolabelled CCL5. Further, both CCL17 and CCL22 act as CCR4 antagonists by inhibiting CCL5-induced migration. Although both CCL17 and CCL22 caused mobilization of intracellular calcium, none of them induced migration or histamine release.

Conclusions These results suggest that CCL5-induced migration of MCs via CCR4 can be regulated by the natural agonists CCL17 and CCL22, which are up-regulated at sites of allergic inflammation.

Get access to the full text of this article

Ancillary